A phase I study of halichondrin B analog E7389 in combination with gemcitabine in patients with refractory or advanced solid tumours.

Next Previous
Trial Profile

A phase I study of halichondrin B analog E7389 in combination with gemcitabine in patients with refractory or advanced solid tumours.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Eribulin (Primary) ; Gemcitabine (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 10 Nov 2015 Results published in the British Journal of Cancer (n = 21).
    • 11 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top